| Calcidiol and PTH levels in women attending an osteoporosis program. | |
| | |
MedLine Citation:
|
PMID: 10089217 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We performed a retrospective study of 237 patients attending a specialty osteoporosis practice. Secondary causes for reduced bone mineral density (BMD) were evaluated in 196 postmenopausal women and 41 premenopausal women; mean age was 56 +/- 13.8 years (mean +/- SD). BMD was measured by dual-energy X-ray absorptiometry (DXA) (QDR 1000W/2000 Hologic). Levels of intact parathyroid hormone (iPTH), calcidiol [25(OH)D], thyroid-stimulating hormone, and 24-hour urinary calcium were measured, and serum and urine protein (SPEP and UPEP) electrophoresis were performed. Overall, 16% of our patients had 25(OH)D levels <15 ng/ml, the lowest acceptable vitamin D level without a concomitant rise in iPTH levels. Among the osteoporotic patients (T score <-2.5 SD), 17% had 25(OH)D levels <15 ng/ml and 7% <10 ng/ml. Among the osteopenic patients (-2.5 < T < -1.0 SD), 11% had 25(OH)D levels <15 ng/ml. Seventeen percent of patients with Z score </=-1.0 SD (low range normal value) had 25(OH)D levels <15 ng/ml. Low 25(OH)D levels were inversely related to high iPTH values (r = 0.30, P < 0.0001). Hypercalciuria was present in 15% of our patients, elevations of PTH levels (>65 pg/ml, upper normal limit of assay) were present in 11.5%, and hyperthyroidism in 4%. A 25(OH)D level of <25 ng/ml in women (n = 86) with no known secondary causes of low BMD was associated with an iPTH level above 49 pg/ml. The measurement of 25(OH)D levels is recommended in the evaluation of secondary causes for reduced BMD. Supplementation with vitamin D appears needed to keep 25(OH)D above 25 ng/ml, the level required to prevent increments in iPTH levels. |
| | |
Authors:
|
S T Haden; G E Fuleihan; J E Angell; N M Cotran; M S LeBoff |
Related Documents
:
|
20213797 - Multiparameter comparison of injection laryngoplasty, medialization laryngoplasty, and ... 2397607 - Development of a double antibody radioimmunoassay for quantitation of 1 alpha,25-dihydr... 9133507 - Activation of the hemostatic mechanism after pharmacological cardioversion of acute non... 8285627 - Interleukin-6, gamma interferon, and tumor necrosis factor receptors in typhoid fever r... 11103757 - Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers ... 20404037 - Thyroid hormone concentrations in systemic circulation and ovarian follicular fluid of ... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Calcified tissue international Volume: 64 ISSN: 0171-967X ISO Abbreviation: Calcif. Tissue Int. Publication Date: 1999 Apr |
Date Detail:
|
Created Date: 1999-05-06 Completed Date: 1999-05-06 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7905481 Medline TA: Calcif Tissue Int Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 275-9 Citation Subset: IM |
Affiliation:
|
Endocrine-Hypertension Division, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Avenue, Harvard Medical School, Boston Massachusetts 02115, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Absorptiometry, Photon Adult Aged Biological Markers / blood, urine Bone Density* / drug effects Calcifediol / blood* Calcium / blood, urine Female Humans Middle Aged Osteoporosis / blood*, etiology, urine* Parathyroid Hormone / blood* Premenopause / blood, urine Proteins / analysis Retrospective Studies Risk Factors Thyrotropin / blood |
| Grant Support | |
ID/Acronym/Agency:
|
5R01 AG12271-03/AG/NIA NIH HHS; K01 AG00666-01/AG/NIA NIH HHS; M01-RR-02635/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Parathyroid Hormone; 0/Proteins; 19356-17-3/Calcifediol; 7440-70-2/Calcium; 9002-71-5/Thyrotropin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Differences between the trypanosomal and human GlcNAc-PI de-N-acetylases of glycosylphosphatidylinos...
Next Document: Influence of skeletal site of origin and donor age on osteoblastic cell growth and differentiation.